MKI67 and breast cancer: Gallen guidelines [14], individual treatment decision is recommended based on clinicopathological factors, such as tumor size, lymph node metastasis status, histological grade, Ki67 labeling index, quantitative expression of hormone receptors, and genomic signature, for stage 2 breast cancer patients when selecting chemotherapy for ER-positive–HER2-negative early-invasive breast cancer.